Details

Autor(en) / Beteiligte

• Ahmadzadehfar, Hojjat
• Matern, Ralf
• Baum, Richard P.
• Seifert, Robert
• Kessel, Katharina
• Bögemann, Martin
• Kratochwil, Clemens
• Rathke, Hendrik
• Ilhan, Harun
• Svirydenka, Hanna
• Sathekge, Mike
• Kabasakal, Levent
• Yordanova, Anna
• Garcia-Perez, Francisco Osvaldo
• Kairemo, Kalevi
• Maharaj, Masha
• Paez, Diana
• Virgolini, Irene
• Rahbar, Kambiz

Titel

The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study

Ist Teil von

• European journal of nuclear medicine and molecular imaging, 2021-11, Vol.48 (12), p.4067-4076

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2021

Link zum Volltext

Quelle

SpringerLink

Beschreibungen/Notizen

• Introduction Prostate-specific membrane antigen (PSMA)-based radioligand therapy (RLT) showed in a multicentre WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) study that the presence of bone metastases is a negative prognosticator for the survival. The current multicentre retrospective analysis aims to evaluate the response rate to RLT, the overall survival (OS) of patients and the safety of the treatment according to the extent of bone involvement. Methods The study included patients with progressive metastatic castration-resistant prostate cancer (mCRPC), who underwent RLT with [ 177 Lu]Lu-PSMA-617 and a follow-up of at least 6 months. Tumour burden in the bone was classified prior to RLT as follows: less than 6 lesions, 6–20 lesions, more than 20 lesions and diffuse involvement. The response rate was evaluated using changes of the prostate-specific antigen (PSA) after the first treatment cycle. Overall survival was calculated from the date of the first treatment. Haematological adverse events were classified according to Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Results A total of 319 males were included in the analysis. The extent of bone metastases and PSA response did not correlate significantly. Any PSA decline was observed in 73% patients; 44% showed a decline of ≥50%. The median OS of patient in the different subgroups was 18 months (less than 6 lesions), 13 months (6–20 lesions), 11 months (more than 20 lesions) and 8 months (diffuse involvement), respectively ( p  < 0.0001). Patients with prior Ra-223-therapy showed longer OS in all subgroups, especially in the subgroups with 6–20 lesions (OS: 16 vs. 12 months; p  = 0.038) as well as diffuse involvement (OS: 11 vs. 7 months; p  = 0.034). Significant negative prognosticators of OS were the existence of liver metastases in all subgroups and prior chemotherapy in patients with <6 bone lesions. Anaemia and thrombocytopenia correlated positively with the extent of bone metastases: p  < 0.0001 and 0.005, respectively. No patient showed a high grade leukopenia. Conclusion The extent of bone involvement correlated negatively with the OS after RLT; however, it showed no relevant correlation with the PSA response rate. Prior therapy with Ra-223 may have a positive impact on OS. Haematotoxicity was higher in patients with more than 20 bone lesions; nevertheless, the majority of these patients did not show a relevant haematotoxicity.